Compare Dell Technologies Inc (DELL) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs DexCom, Inc. — how do they compare? Dell Technologies Inc trades at $581 (market cap $365.31B), while DexCom, Inc. trades at $84.38 (market cap $31.86B). The key difference: Dell Technologies Inc is far larger — about 11.5× DexCom, Inc.'s market cap, and Dell Technologies Inc pays a 0.44% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and DexCom, Inc. for 62 Days on average.
| DELL | DXCM | |
|---|---|---|
Market Cap | $365.31B | $31.86B |
Volume | 5,121,365 | 3,607,070 |
Sector | Technology | Health |
52-Week High | $588.67 | $92.34 |
52-Week Low | $111.10 | $54.84 |
Typical Hold Time | 57 Days | 62 Days |
Enterprise Value | $388.20B | $31.32B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies (DELL) trades at $578.96, up 0.9% with strong bullish momentum driven by AI server demand. The stock shows robust technical positioning above key support levels with a P/E of 33.42 and net income margin of 7.53%. Recent earnings beats and raised AI revenue guidance to $74 billion highlight operational strength. Analyst consensus remains positive with 55.6% buy ratings and a $566.35 price target.
Dell presents compelling growth prospects from its AI server backlog expansion and margin improvements, though elevated valuation and competitive pressures warrant caution. The company's guidance increase and dividend growth signal confidence, but investors should monitor execution risks in the rapidly evolving AI infrastructure market.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
